Summary: Lymphocytes derived from rats bearing DAB-induced hepatic carcinoma at progressive stages (micro-and macroscopically) were stimulated by three mitogens; PHA, Con A and PWM. A remarkable increase in 3H-thymidine uptake was found over the period from the stage proceeding the appearance of carcinoma to the early stage of carcinogenesis, while a remarkable decrease of 3H-thymidine uptake was revealed in lymphocytes of advanced tumor-bearing rats. This result is very remarkble, for it questions the generally believed assumption that immune ability decreases from the early stage of carcinogenesis.
Introduction
Each living organism posseses a defense mechanism by which it can discriminate between self and nonself. It recognizes determinants on pathogenic antigens and initiates a complex immune response to exclude them. What response, then, dose a carcinoma bearing organism exhibit toward carcinomatous cells borne in itself? Burnet (1970) proposed the concept of immunological surveillance, a mechanism for eliminating or inactivating dangerous mutant cells. Once cells have escaped from this mechanism, they may still be immunological targets of the tumor -bearing host. The major host defense against carcinoma is effected by cellular immunity, similar to the reaction of a recipient to a tissue allograft (Bell, 1972) . Activated T lymphocytes, natural killer cells and antibody-dependent K cells all contribute to the maintenance of a cellular immune offector mechanism (Herberman et al. 1978; Zinkernagel et al. 1974) . It has been well documented that a significant decrease in immune response occurs in patients with certain malignances (Fairly 1969; Sharman et al. 1966; Trubowits et al. 1966; Brooks et al. 1972) . Such a subnormal response in number and function of lymphocytes seems to correlate with suppressive cells and serological factors in tumor-bearing host (Brooks et al. 1972; Berendt et al. 1980; Sample et al. 1971; McMaster et al. 1977; Krant et al. 1968) In the case of human carcinoma the more advanced the stage of disease, the lower the level of cellular immunity.
It is of interest to understand the relationship between the immune ability of carcinomabearing host and the tumor. We may begin this process by studying the chronological changes in the immune ability of the tumor-bearing host, including proliferation, infiltration and metastasis of carcinoma.
Further developments would not only lead to early diagnosis and inproved prognosis but also new treatments, including immunological therapy of carcinoma (Savel 1963) . Great differences in the mode of and velocity of development, the original sites of carcinogenesis, and the histological types have made it difficult to assess properly the host's immune ability even though they are classified by genetic difference, sex, age and stage of illness. We overcame this problem by employing an inbred strain of rat and orally administrating p-dimethylaminoazobenzene (DAB) mixed with food to induce a hepatic carcinoma at a high frequency. Lymphocytes proliferate and synthesize RNA and DNA when stimulated by a variety of mitogens as well as by antigens. This phenomenon, called lymphocyte transformation has been used to assess immunologic competence (Stobo, 1972; Veit et al. 1976) . Several mitogens selectively act on different lymphocyte subpopulations in a polyclonal fashion. Con A stimulates both immature and mature T cells, whereas PHA only stimulates mature T cells. PWM is a T cell dependent-B cell activator.
Peripheral T lymphocytes are also activated by these mitogens.
Lymphocyte transformations by mitogens were examined with the lapse of time as an indicator of immunologic reactivity. As reported by several authors in the response of lymphocytes of cancer patients to phytohemagglutinin (PHA) (Garrioch et al. 1970; Ducos et al. 1970; Orita et al. 1973) , the blast formation of lymphocytes in rats during advanced stage of DAB hapatic carcinoma was suppressed.
However, a marked increase in mitogen response was observed during the early sage of carcinomatoses. Such a high reactivity of lymphocytes at this stage seems to suggest that the host's immune is stimulated by the presence of carcinomatous cells to inhibit their prolif eration.
Materials and Methods
Experimental animals and DAB hepatic carcinoma
Forty male rats of JAC Wistar strain, 5 weeks of age weighing about 110 g, were used. Thirty rats were used for the production of DAB hepatic carcinoma (experimental group) and fed a compressed CLEA-CE2 diet containing 0.06% DAB up to 275 days from the beginning of the experiment.
Food intake was about 12g-13g per day per an animal. Ten rats were fed a normal CLEA-CE2 diet as a control group.
Surviving rats (Table 1 ) from the experimental group were examined for the degree of proliferation and development of hepatic tumors.
The following criteria were used to discriminate the stage or grade of tumor development: Blood specimens were collected with heparin from the abdominal vena cava and diluted with two volumes of Eagle's minimum essential medium (EMEM, GIBCO, NY). This mixture was layered over 2.5 ml of Ficoll-Hypaque (Pharmacia), centrifuged at 1000 G for 30 min at room temperature and the mononuclear cell layer collected.
The cells were washed three times in EMEM by centrifugation at 1000 G for 7 min and suspended in RPMI- (Waxdal, 1975; Morisawa et al. 1979) . A preliminary experiment to determine the optimal mitogen concetrations indicated that lymphocytes from normal controls and DAB-treated rats in several stages of carcinogeneses showed a similar dose requirement for the blast transformation by PHA, Con A or PWM.
Results
PHA response : Rats were sacrificed ofter 275 days and the grade of carcinoma was determined.
Concomitantly, the mitogen response was assayed. Fig. 1 shows that rats with advanced tumor (grade III or N) gave a much lower index than normal animals. On the other hand, it should be noted that some rats with an early stage of carcinogenesis (grade I or II of severity) gave a several times higher S. I. than control animals.
The S. I. for each grade of carcinoma is given in Table 2 . The mean S.I. value of normal rats was 5.4±2.9.
Con A response: The results obtained by con A stimulation were comparable to those from PHA response (Fig. 2) . The values were smaller than those of controls. 
Discussion
Rapid progress has been made in immunologic studies on tumor. Nevertheless, little is known about the presence of specific immunity to human carcinoma. There is ample evidence supporting a decrease in immune ability of patients with the progression in severity of cancer. Carcinoma cells possess tumor-specific transplantation antigens (TSTA) or tumor-associated antigens (TAA), to which animals can respond often resulting in death of the malignant cells in vitro. It is believed that the body's rejection of mutant or neoplastic cells is performed by cellular immunity mechanisms for which the action of several types of lymphocytes is responsible.
Immune response is a well-organized reaction involving T cells, B cells, macrophages and other cells. In particular, some defined subpopulation of T cells, such as the of f ector cells in delayed type hypersensitivity and killer T cells, exert various functions on tumor immunity (Zinkernagel et al. 1974) . Involvement of non-T, non-B lymphocytes, termed natural killer (NK) cells and K cells, in the rejection of tumors has also been proposed (Herberman et al. 1978) . In addition, activated lymphocytes in response to carcinomatous antigens produce many mediators which are destructive to tumor cells. They include mitogenic factor, macrophage inhibitory factor (MIF), lymphotoxin, and inflammatory and transfer factors.
Despite the development of these immune responses, tumors carrying TSTA are not suppressed in vivo but allowed to grow in some cases. This has been explained by the production of immunosuppressive factors (Hellstrom et al. 1977; Baldwin et al. 1976; Sjogren et al. 1971) , immunological tolerance, and immunological enhancement in cancer patients (Prehn et al. 1971) .
Other investigators have reported suppression of immunocompetent cells in tumor-bearing hosts that were mediated by suppressor cells (Berendt et al. 1980; Fujimoto et al. 1976; Han et al. 1979; Gautam et al. 1979; Hubbard et al. 1981) . Immunological enhancement seems to be best explained by this immunosuppressor cell mechanism (Hellstrom et al. 1978) .
There is no doubt that TSTA is present on carcinomatous cells. The authors have already reported the presence of TSTA or TAA from the biochemical and immunohistological studies (Kawasaki et al. 1971 (Kawasaki et al. , 1977 . In many cases TSTA plays an important role in tumor immunity for the suppression of carcinomatous cells (Foley, 1953; Hellstrom et al. 1967 Hellstrom et al. , 1970 Parmiani et al. 1975) .
Comparison of immature abilities will not give any reliable results in human carcinoma for the reasons mentioned above. In the present model, DAB induced hepatic carcinoma developed in inbred rat strains. The whole course of disease, including the stage before the appearance of carcinoma and the subsequent stages of onset, proliferation, infiltration, and metastasis, was divided into six stages (0 through V) macroscopically and histologically. Lymphocytes were prepared from these rats as well as from normal control rats and incubated with PHA, Con A and PWM. The rise and fall of blastoid cell transformation as an indicator of immune ability demonstrates a remarkable increase in the uptake of 3 H-thymidine in the early stages of carcinogenesis.
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